Fa Pharm Immunology

Front 1

cyclosporine

Back 1

bind to cyclophilins. complex blocks the differentiation and activation of TC by inhibition calcineurin; preventing the production of IL 2 and its receptor

use: suppresses organ rejection after transplant. selected autoimmune disorders.

toxicity: predisposes patients to viral infections and lymphoma; nephrotoxic (prevent with mannitol diuresis)

Front 2

tacrolimus (FK506)

Back 2

simliar to cyclosporine; binds to FK binding protein, inhibiting secretion of IL2 and other cytokines.

use: potent immunosuppressive used in organ transplant recipients.

toxicity: significant - nephrotoxicity, peripheral neuropathy, hypertension, pleural effusion, hyperglycemia.

Front 3

azathioprine

Back 3

antimetabolite precursor of 6-mercaptopurine that interferes with the metabolism and synthesis of nucleic acids. toxic to proliferating lymphocytes.

use: kidney transplantation, autoimmune disorders (including glomerulonephritis and hemolytic anemia).

toxicity: BM suppression. active metabolite mercaptopurine is metabolized by xanthine oxidase; thus toxic effects may be increased by allopurinol.

Front 4

muromonab-cd3 (OKT3)

Back 4

monoclonal ab that bind to CD3 (epsilon chain) on the surface of TC. blocks cellular interaction with CD3 protein responsible for TC signal transduction.

use: immunosuppression after kidney transplantation.

toxicity: cytokine release syndrome, hypersensitivity reaction.

Front 5

sirolimus (rapamycin)

Back 5

binds to mTOR (mammalian target of rapamycin). inhibits TC proliferation in response to IL2.

use: immunosuppression after kidney transplant in combination with cyclosporine and coritcosteriods.

toxicity: hyperlipidemia, thrombocytopenia, leukopenia.

Front 6

mycophenolate mofetil

Back 6

inhibits de novo guanine synthesis and blocks lymphocyte production.

Front 7

daclizumab

Back 7

monoclonal antibody with high affinity for the IL2 receptors on activated TC.

Front 8

recombinant cytokines and clinical uses

aldesleukin (IL2)

Back 8

renal cell carcinoma, metastatic melanoma

Front 9

recombinant cytokines and clinical uses

erythropoietin (epoetin)

Back 9

anemias (esp. in renal failure)

Front 10

recombinant cytokines and clinical uses

filgrastim (granulocyte colony stimulating factor)

Back 10

recovery of BM (ie. propylthiouracil or methimazole)

Front 11

recombinant cytokines and clinical uses

sargramostim (granulocyte-macrophage colony-stimulating factor)

Back 11

recovery of bone marrow

Front 12

recombinant cytokines and clinical uses

a-interferon

Back 12

hepatitis b, c, karposi's sarcoma, leukemias, malignant melanomas

Front 13

recombinant cytokines and clinical uses

b-interferon

Back 13

ms

Front 14

recombinant cytokines and clinical uses

g-interferon

Back 14

chronic granulomatous diease = NADPH oxidase deficiency

Front 15

recombinant cytokines and clinical uses

oprelvekin (IL 11)

Back 15

thrombocytopenia

Front 16

recombinant cytokines and clinical uses

thrombopoietin

Back 16

thrombocytopenia